^
    Back
    Association details:
    Biomarker:KRAS wild-type
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:gemcitabine (DNA synthesis inhibitor) +
    albumin-bound paclitaxel (Bcl2 inhibitor, Tubulin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Clin Cancer Res
    Title:

    Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma

    Published date:
    02/18/2022
    Excerpt:
    Of the 2,483 patients (male 53.7%, median-age 66 years) studied, 266 tumors (10.7%) were KRAS-WT….Real-world evidence reveals a survival advantage of KRAS-WT patients in overall cohorts as well as in patients treated with gemcitabine/nab-paclitaxel or 5FU/oxaliplatin.
    DOI:
    10.1158/1078-0432.CCR-21-3581
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer
    Title:

    Kras Gene Analysis Using Liquid-Based Cytology Specimens Predicts Therapeutic Responses and Prognosis in Patients with Pancreatic Cancer

    Published date:
    01/21/2022
    Excerpt:
    ...unresectable PDAC patients who underwent first-line therapy with gemcitabine and nab-paclitaxel (GA)...Of the 110 patients analyzed, 15 had wild-type Kras. Those with the wild-type gene showed significantly longer PFS and OS than those with mutant Kras (6.9/5.3 months (p = 0.044) vs. 19.9/11.8 months (p = 0.037), respectively).
    DOI:
    https://doi.org/10.3390/cancers14030551